Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: CymaBay falls on Phase IIb gout data

    CymaBay Therapeutics Inc. (NASDAQ:CBAY) fell $2.27 (19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate (MBX-102) to treat gout.While the trial met its primary endpoint -- with…

    Published on 2/24/2015
  • CLINICAL NEWS: Teva's migraine therapy meets Phase II endpoints

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said TEV-48125 (LBR-101) met the primary endpoint of reducing headaches vs. placebo in a Phase IIb trial to treat chronic migraine.The 261-patient study tested two doses …

    Published on 2/24/2015
  • CLINICAL NEWS: Novo's oral GLP-1 meets Phase II endpoint

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) gained $2.38 to $47.55 in New York and DKK13.10 to DKK310.4 in Copenhagen on Friday after it said oral semaglutide (OG217SC) met the primary endpoint of a 600-patient Phase II trial …

    Published on 2/20/2015
  • CLINICAL NEWS: NIAID, HVTN launch African trial of HIV vaccine

    NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) started the Phase I/II HVTN 100 trial in South Africa to evaluate combination vaccine HVTN 100 to prevent HIV…

    Published on 2/19/2015
  • CLINICAL NEWS: TB Alliance begins Phase I trial of TBA-354

    The not-for-profit Global Alliance for TB Drug Development began a U.S. Phase I trial of tuberculosis (TB) treatment TBA-354. TB Alliance said the next generation nitroimidazole is the first new TB candidate to enter …

    Published on 2/19/2015
  • CLINICAL NEWS: Eylea tops Lucentis, Avastin in some DME patients

    A comparative effectiveness study of anti-VEGF drugs to treat diabetic macular edema (DME) showed that Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) led to greater improvements in vision than did …

    Published on 2/18/2015
  • CLINICAL NEWS: Takeda's motesanib misses in Asian trial

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will terminate the Phase III MONET-A trial of motesanib diphosphate (AMG 706) to treat stage IV or recurrent non-small cell lung cancer (NSCLC) after the candidate …

    Published on 2/17/2015
  • CLINICAL NEWS: VBL sinks on Phase II psoriasis, UC data

    VBL Therapeutics Ltd. (NASDAQ:VBLT) lost $9.24 (65%) to $4.87 on Tuesday after lead compound VB-201 missed the primary and secondary endpoints in two Phase II trials to treat plaque psoriasis and ulcerative colitis (UC…

    Published on 2/17/2015
  • CLINICAL NEWS: Takeda's ixazomib meets PFS endpoint in myeloma study

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said an interim analysis of the Phase III TOURMALINE-MM1 trial showed ixazomib (MLN9708) met the primary endpoint of increasing PFS in patients with relapsed or refractory …

    Published on 2/10/2015
  • CLINICAL NEWS: Regulus falls on Phase I HCV data

    Regulus Therapeutics Inc. (NASDAQ:RGLS) fell $1.22 to $15.64 on Monday after reporting data from a Phase I study of RG-101 to treat HCV, including follow-up results from a cohort receiving a single 2 mg/kg dose and top-…

    Published on 2/9/2015
  • CLINICAL NEWS: Adocia climbs on fast-acting insulin data

    Adocia S.A. (Euronext:ADOC) rose EUR 9.62 (15%) to EUR 73.40 after the company's HinsBet fast-acting insulin met the primary endpoint of an increase in recombinant human insulin bioavailability during the first hour …

    Published on 2/6/2015
  • CLINICAL NEWS: Genmab climbs on Phase II daratumumab data

    Genmab A/S (CSE:GEN; OTCBB:GMXAY) rose DKK46 (11%) to DKK471 in Copenhagen after partner Janssen Biotech Inc. reported preliminary results from a Phase II trial of daratumumab in relapsed or refractory multiple myeloma…

    Published on 2/4/2015
  • CLINICAL NEWS: Amgen's biosimilar Humira meets in RA equivalence trial

    Amgen Inc. (NASDAQ:AMGN) said its ABP 501 met the primary endpoint of equivalence, as measured by ACR20 at week 24, to Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in a Phase III trial to treat moderate to severe …

    Published on 2/3/2015
  • CLINICAL NEWS: Isis falls on Phase II diabetes data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS) lost $3.97 to $64.70 on Tuesday after releasing top-line data from its Phase II trial of ISIS-PTP1BRx to treat Type II diabetes. The company said patients treated with ISIS-…

    Published on 2/3/2015
  • CLINICAL NEWS: Ardelyx falls on tenapanor Phase II data

    Ardelyx Inc. (NASDAQ:ARDX) fell $7.76 (29%) to $19.25 on Monday after it said tenapanor (AZD1722) met the primary endpoint in a Phase IIb trial to treat hyperphosphatemia but led to rates of diarrhea that were "…

    Published on 2/2/2015
  • CLINICAL NEWS: Egalet jumps on data for abuse-deterrent morphine

    Egalet Corp. (NASDAQ:EGLT) climbed $1.18 (24%) to $6.11 on topline data from a human abuse liability study showing that 60 mg Egalet-001, an abuse-deterrent, extended-release, oral formulation of morphine, demonstrated …

    Published on 1/22/2015
  • CLINICAL NEWS: AZ's long-term Brilinta thinking

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said anticoagulant Brilinta ticagrelor met the primary endpoint in a cardiovascular (CV) outcomes study evaluating long-term use of the drug beyond one year.AZ said twice-daily dosing…

    Published on 1/14/2015
  • CLINICAL NEWS: BMS's kingly Opdivo NSCLC data

    Bristol-Myers Squibb Co. (NYSE:BMY) said it ended the Phase III CheckMate -017 trial of Opdivo nivolumab to treat advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) after an independent data …

    Published on 1/12/2015
  • CLINICAL NEWS: Argos falls on Phase IIb miss in HIV

    Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy …

    Published on 1/9/2015
  • CLINICAL NEWS: Once-every-four-weeks alirocumab meets in Phase III study

    Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the first trials assessing once-every-four-weeks doses of alirocumab (REGN727, SAR236553) to treat hypercholesterolemia…

    Published on 1/9/2015
  • CLINICAL NEWS: Portola's Factor Xa antidote meets Phase III endpoint

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $2.01 to $30.33 on Friday after its andexanet alfa met the primary endpoint in the first part of the Phase III ANNEXA-R study to reverse the anticoagulant activity of …

    Published on 1/9/2015
  • CLINICAL NEWS: Bind gains after NSCLC update

    Bind Therapeutics Inc. (NASDAQ:BIND) jumped $1.91 (37%) to $7.06 on Thursday after reporting it had enrolled the first patient in a Phase II study of BIND-014 to treat non-small cell lung cancer (NSCLC) patients with a …

    Published on 1/8/2015
  • CLINICAL NEWS: Biogen reports mixed Phase II results for LINGO antibody

    Biogen Idec Inc. (NASDAQ:BIIB) said BIIB033 did not meet its primary or secondary endpoints in the Phase II RENEW trial to treat acute optic neuritis (AON) but termed the results "encouraging" by providing the first …

    Published on 1/8/2015
  • CLINICAL NEWS: GW's epilepsy timetable eclipses Sativex cancer miss

    Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up shares of GW Pharmaceuticals plc (NASDAQ:GWPH; LSE:GWP) by 13% on NASDAQ after the company said it expects to begin reading out…

    Published on 1/8/2015
  • CLINICAL NEWS: Neurocrine jumps on Phase III endometriosis data

    Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $5.60 (26%) to $27.48 on Thursday after partner AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met its co-primary endpoints in the Phase III M12-665 trial to treat …

    Published on 1/8/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993